RVMD vs. MRTX, KYMR, ARGX, BNTX, NBIX, QGEN, RGEN, PCVX, EXEL, and HALO
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include Mirati Therapeutics (MRTX), Kymera Therapeutics (KYMR), argenx (ARGX), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector.
Mirati Therapeutics (NASDAQ:MRTX) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings.
Mirati Therapeutics currently has a consensus price target of $60.00, indicating a potential upside of 2.21%. Revolution Medicines has a consensus price target of $43.20, indicating a potential upside of 12.71%. Given Mirati Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Revolution Medicines is more favorable than Mirati Therapeutics.
In the previous week, Revolution Medicines had 3 more articles in the media than Mirati Therapeutics. MarketBeat recorded 3 mentions for Revolution Medicines and 0 mentions for Mirati Therapeutics. Mirati Therapeutics' average media sentiment score of 1.14 beat Revolution Medicines' score of 0.00 indicating that Revolution Medicines is being referred to more favorably in the news media.
Mirati Therapeutics received 392 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 69.15% of users gave Revolution Medicines an outperform vote while only 64.82% of users gave Mirati Therapeutics an outperform vote.
Revolution Medicines has a net margin of 0.00% compared to Revolution Medicines' net margin of -1,900.65%. Mirati Therapeutics' return on equity of -36.41% beat Revolution Medicines' return on equity.
Revolution Medicines has lower revenue, but higher earnings than Mirati Therapeutics. Revolution Medicines is trading at a lower price-to-earnings ratio than Mirati Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mirati Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.
94.3% of Revolution Medicines shares are owned by institutional investors. 3.3% of Mirati Therapeutics shares are owned by insiders. Comparatively, 8.0% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Revolution Medicines beats Mirati Therapeutics on 16 of the 19 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
